ClinicalTrials.gg
RecruitingNCT05794425Updated Nov 29, 2023

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

A Phase 1/2 interventional study of Cyclosporine A and Umbilical cord blood & Umbilical cord derived mesenchymal stem cells in Bone Marrow Failure Disorders, sponsored by Shandong Qilu Stem Cells Engineering Co., Ltd.. Recruiting at 8 sites in China. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Shandong Qilu Stem Cells Engineering Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Study summary

The multicenter collaborative clinical study conducted a systematic clinical observation in the treatment of bone marrow failure diseases via UCB\&UC-MSCs , in order to observe its clinical efficacy and safety.

02

Conditions studied

  • Bone Marrow Failure Disorders
03

In context

Bone Marrow Failure Disorders

91 studies on the registry are indexed under Bone Marrow Failure Disorders; 29 are open to participants now.

This study's planned enrollment of 100 is above the median of 26 across 69 interventional studies indexed under Bone Marrow Failure Disorders.

Browse Bone Marrow Failure Disorders studies →

Lead sponsor

Shandong Qilu Stem Cells Engineering Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with bone marrow failure disorders, including aplastic anemia, pure red cell aplastic anemia, immune-related pancytopenia, paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, acute arrest of hemopoiesis, and cytopenia of unknown significance;
  2. Patients with no severe impairment of liver and kidney function (total (TBIL): ≤ 1.5×; or AST: ≤ 2.5×ULN; Alkaline phosphatase: ≤ 3×ULN; Serum creatinine: ≤ 1.5×ULN);
  3. The (PT) or activated partial thrombin time (APTT) or international normalized ratio (INR): ≤ 1.5×ULN in the absence of anticoagulant therapy;
  4. The (LVEF): ≥50% by cardiac echocardiography
  5. surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) were negative. If any of the above items is positive, the HBV DNA titer in peripheral blood must be lower than the detection limit or 1×10\^3 copys/ml;
  6. Patients with no plans for stem cell transplantation;
  7. Patients with 0-2;
  8. Those who voluntarily participate in this clinical study and have signed an .

Exclusion criteria

Exclusion Criteria:

  1. Patients who have suffered malignant tumors other than squamous cell carcinoma of the skin, basal cell carcinoma of the skin, malignant melanoma cured by surgery, and carcinoma in situ of the cervix in the past 5 years;
  2. Patient with severe cardiac insufficiency (e.g. grade Ⅲ、Ⅳ by classification NYHA), and medically uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥110 mmHg);
  3. Patients with severe mental illness;
  4. Patients with infection should be recruited with delay;
  5. or ALT: above 3 times the , creatinine, total , or alkaline: phosphatase (ALP): above 1.5 times the upper limit of normal;
  6. Patients with test positive for , or syphilis;
  7. Patients with severe allergies or allergic to the active ingredients, of the drug, or blood products in this clinical trials;
  8. Patients who are pregnant or breastfeeding, or have a childbirth plan in the near future;
  9. Patients receive /autologous hematopoietic stem cell transplantation by the assessment of investigators;
  10. There are other conditions that the investigators consider inappropriate for inclusion.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cyclosporine A

    Drug: Cyclosporine A

  • Experimental
    UCB+UC-MSCs

    Biological: Umbilical cord blood & Umbilical cord derived mesenchymal stem cells

Interventions

  • 3-5 mg per kilogram per day.

  • BiologicalUmbilical cord blood & Umbilical cord derived mesenchymal stem cells

    Intravenous infusion of umbilical cord blood and umbilical cord derived mesenchymal stem cells (5-8×10\^7) at 1 week interval.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    To evaluate efficacy of UCB in combination with UC-MSCs in the treatment of bone marrow failure disorders

    Time frame: Up to two years

Secondary outcomes

  1. Progression-free Survival (PFS)

    To assess Progression-free Survival (PFS) of the combination

    Time frame: Up to two years

  2. Overall Survival (OS)

    To assess overall survival (OS) of the combination

    Time frame: Up to two years

07

Study locations

8 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Apr 2025, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 3, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2026
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05794425
Lead sponsor
Shandong Qilu Stem Cells Engineering Co., Ltd.
Collaborators
Shandong Provincial Third Hospital, Dezhou People's Hospital, Children's Hospital Affiliated to Shandong University, The Second Affiliated Hospital of Shandong First Medical University, Tai'an Central Hospital, Linyi People's Hospital, Linyi Central Hospital, Rizhao People's Hospital, Lanling People's Hospital, Jining First People's Hospital, The affiliated hospital of Jining medical college, Zibo municipal hospital, Binzhou People's Hospital, The Affiliated Hospital of Binzhou Medical College, Shengli Oilfield Central Hospital, Weihai Municipal Hospital, Weihai Central Hospital, Shandong University of Traditional Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine (TCM), Wuwei People's Hospital, Gansu Wuwei Tumor Hospital, The Second Affiliated Hospital of Harbin Medical University, Yuncheng Institute of Hematology, Kaifeng Central Hospital, Zhengzhou Central Hospital, Air Force Hospital of Western War Zone, The First People' s Hospital of Yunnan Province, Zigong No.1 Peoples Hospital, The First People's Hospital of Jingzhou, Jiangxi Province Children's Hospital, Second Affiliated Hospital of Zhengzhou University, Yantai Ludong Hospital (Shandong Provincial Hospital Group)
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Aug 1, 2023
Primary completion
Apr 2025 (estimated)
Completion
Apr 2026 (estimated)
Last update
Nov 29, 2023

Study contacts

zhe Yu, MD
Contact
doctoryu1120@163.com
86-18753103739
zhe Yu, MD
principal investigator · Shandong Provincial Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion